Annals of Oncology Advance Access originally published online on September 9, 2007
Annals of Oncology 2007 18(12):2025-2029; doi:10.1093/annonc/mdm366
© 2007 European Society for Medical Oncology
phase I and pharmacokinetics |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
1 Department of Clinical Pharmacology, University of Oxford, Oxford, UK
2 Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
3 Department of Medical Oncology, University of Oxford, Oxford, UK
4 Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline, Research Triangle Park, USA
* Correspondence to: Dr R. Midgley, Cancer Research UK Medical Oncology Unit, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK. Tel: +44-1865-226054; Fax +44-1865-226179; E-mail: Rachel.Midgley{at}cancer.org.uk
Background: This study determined the optimally tolerated regimen (OTR) of oral lapatinib administered in combination with infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) and assessed the safety, tolerability and pharmacokinetics of the combination.
Patients and methods: Twenty-five patients were enrolled; 12 patients were treated at three dose levels to determine OTR; then 13 patients were treated at OTR to evaluate the pharmacokinetics of the combination.
Results: The 2-weekly OTR comprised lapatinib 1250 mg/day with irinotecan 108 mg/m2 (day 1) and leucovorin 200 mg/m2, 5-FU bolus 240 mg/m2 and 5-FU infusion 360 mg/m2 (days 1 and 2); doses of 5-FU and irinotecan represent a 40% reduction in dose compared to conventional FOLFIRI. Dose-limiting toxicities were grade 3 diarrhoea and grade 4 neutropenia. Co-administration of lapatinib increased the area under the plasma concentration-time curve of SN-38, the active metabolite of irinotecan, by an average of 41%; no other pharmacokinetic interactions were observed. Of 19 patients evaluable for disease response assessment, four patients had partial response and nine patients had stable disease.
Conclusion: The combination of lapatinib and FOLFIRI is safe and demonstrates clinical activity; the documented PK interaction can effectively be compensated by lowering the doses of 5-FU and irinotecan. This regime may be further tested in a phase II trial.
Key words: colorectal cancer, FOLFIRI chemotherapy, phase I, lapatinib
Received for publication June 22, 2007. Accepted for publication June 25, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-l. Dai, A. K. Tiwari, C.-P. Wu, X.-d. Su, S.-R. Wang, D.-g. Liu, C. R. Ashby Jr., Y. Huang, R. W. Robey, Y.-j. Liang, et al. Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2 Cancer Res., October 1, 2008; 68(19): 7905 - 7914. [Abstract] [Full Text] [PDF]
|
|